Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2
- Immunoglobulin Y (IgY): This type of antibody found in egg yolks can be generated in hens by immunizing them with a vaccine containing the virus or its proteins, according to the UC Davis School of Veterinary Medicine. Studies have shown that these anti-Spike-S1 IgYs can block the binding of the SARS-CoV-2 spike protein to the human ACE2 receptor, the main entry point for the virus into cells. They also demonstrate neutralizing activity against various SARS-CoV-2 spike protein mutants and even SARS-CoV in vitro. IgY offers advantages as a potential prophylactic or therapeutic option due to its relatively low production cost, ease of generation in large quantities, and favorable safety profile.
- Modified Ovalbumin: A modified version of ovalbumin, a major egg white protein, called 3-hydroxyphthalic anhydride-modified chicken ovalbumin (HP-OVA), has been shown to inhibit SARS-CoV-2 infection by disrupting the interaction of the spike protein with the host ACE2 receptor.
- Other Egg Proteins: Other egg proteins like ovomucin, ovotransferrin, lysozyme, cystatin, and sialic acid derivatives have also been reported to have antiviral properties, including against influenza and gastroenteritis viruses. Some of these may exert antiviral activity by interacting with viral proteins like the spike protein, though further research is needed to fully elucidate their mechanisms.
- These findings are based on laboratory studies, and further research is needed to confirm their efficacy and safety in humans.
- Naturally occurring antibodies against SARS-CoV-2 are not found in eggs unless hens are specifically immunized with the virus or its proteins.
- The use of IgY-based therapeutics would likely involve specific formulations and administration methods (e.g., intranasal or oral sprays) rather than simply consuming eggs.
Abstract
The SARS-CoV-2 virus is still spreading worldwide, and there is an urgent need to effectively prevent and control this pandemic. This study evaluated the potential efficacy of Egg Yolk Antibodies (IgY) as a neutralizing agent against the SARS-CoV-2. We investigated the neutralizing effect of anti-spike-S1 IgYs on the SARS-CoV-2 pseudovirus, as well as its inhibitory effect on the binding of the coronavirus spike protein mutants to human ACE2. Our results show that the anti-Spike-S1 IgYs showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro. It might be a feasible tool for the prevention and control of ongoing COVID-19.
Keywords: Chicken Egg Yolk Antibodies; IgY; Neutralizing agent; SARS-CoV-2; Spike protein variants.
Copyright © 2020 Elsevier B.V. All rights reserved.
Similar articles
-
Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.
J Appl Microbiol. 2022 Mar;132(3):2421-2430. doi: 10.1111/jam.15340. Epub 2021 Nov 3.PMID: 34706134 Free PMC article. -
Int Immunopharmacol. 2022 Nov;112:109280. doi: 10.1016/j.intimp.2022.109280. Epub 2022 Sep 28.PMID: 36183680 Free PMC article.
-
Int Immunopharmacol. 2020 Aug;85:106654. doi: 10.1016/j.intimp.2020.106654. Epub 2020 Jun 3.PMID: 32512271 Free PMC article. Review.
-
Antiviral Immunoglobulins of Chicken Egg Yolk for Potential Prevention of SARS-CoV-2 Infection.
Viruses. 2022 Sep 26;14(10):2121. doi: 10.3390/v14102121.PMID: 36298676 Free PMC article. -
Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Front Immunol. 2021 Dec 22;12:732690. doi: 10.3389/fimmu.2021.732690. eCollection 2021.PMID: 35003058 Free PMC article. Review.
Cited by
-
Front Immunol. 2022 Jun 1;13:899617. doi: 10.3389/fimmu.2022.899617. eCollection 2022.PMID: 35720389 Free PMC article. Clinical Trial.
-
PLoS One. 2024 Feb 9;19(2):e0297864. doi: 10.1371/journal.pone.0297864. eCollection 2024.PMID: 38335158 Free PMC article.
-
Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.
J Appl Microbiol. 2022 Mar;132(3):2421-2430. doi: 10.1111/jam.15340. Epub 2021 Nov 3.PMID: 34706134 Free PMC article. -
Toxins (Basel). 2022 Jul 4;14(7):459. doi: 10.3390/toxins14070459.PMID: 35878197 Free PMC article.
-
Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases.
Front Immunol. 2021 Jun 9;12:696003. doi: 10.3389/fimmu.2021.696003. eCollection 2021.
View this post on Instagram